首页> 美国卫生研究院文献>Clinical and Translational Radiation Oncology >PATRIOT: A phase I study to assess the tolerability safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
【2h】

PATRIOT: A phase I study to assess the tolerability safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

机译:爱国者(PATRIOT):一项I期研究旨在评估特定的共济失调毛细血管扩张和Rad3相关(ATR)抑制剂(AZD6738)作为单一药物并结合姑息性放射疗法对实体瘤患者的耐受性安全性和生物学效应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
机译:PATRIOT是ATR抑制剂AZD6738的I期研究,作为单一疗法,与姑息放疗联合使用。在这里,我们描述了这项研究的方案,该方案于2014年开放,目前正在招募中,包括药物和放疗的剂量递增以及扩展队列。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号